DIFLUZOL

Cryptococcosis, including cryptococcal meningitis and infections of other localizations (e.g., lungs, skin). Treatment of patients HIV carriers and AIDS patients, patients after organ transplantation and other patients who receive therapy with immunosuppressants. Fluconazole may be used as maintenance therapy to prevent the recurrence of cryptococcal meningitis in patients with AIDS. Generalized candidiasis, including candidaemia, disseminated candidiasis, and other forms of invasive candida infection (lesion of abdominal cavity, endocardium, eyes, respiratory and urinary tract). Treatment of patients with malignant neoplasms who are in the ICU and receiving cytostatic and immunosuppressive therapy or are influenced by other factors, which makes them more prone to developing candidiasis. Mucous membrane candidiasis: lesions of the oropharynx, esophagus, non-invasive bronchopulmonary infection, candiduria, mucocutaneous and chronic atrophic candidiasis (candidiasis, caused by denture). Treatment of HIV carriers and AIDS patients. To prevent recurrence of oropharyngeal candidiasis in patients with AIDS. Genital candidiasis, including vaginal candidiasis, acute or recurrent, and candidal balanitis. Prophylactic use to reduce the frequency of recurrent vaginal candidiasis (3 or more recurrences per year). Prevention of fungal infections in patients with malignancy who are predisposed to such infections due to chemotherapy or radiation therapy. Ringworm – athlete's foot, athlete's smooth skin, inguinal ringworm, tinea versicolor, ringworm of the nails (onychomycosis) and dermal Candida infections. Deep endemic mycoses in patients with an intact immune system, coccidioidomycosis, paracoccidioides, sporotrichosis and histoplasmosis.